GMAB
Genmab·NASDAQ
--
--(--)
--
--(--)
Genmab (GMAB) Company Profile
Genmab A/S
An international biotechnology company focused on creating and developing innovative antibody therapeutics
Biotechnology Ⅲ
06/11/1998
07/18/2019
NASDAQ Stock Exchange
3,029
12-31
Depository Receipts (Ordinary Shares)
Carl Jacobsens Vej 30, 2500 Valby, Denmark
Develops and commercializes antibody-based therapeutics.
Genmab A/S was incorporated on June 11, 1998. The Company is an international biotechnology company with a portfolio of novel antibody-based products and product candidates designed to meet the medical needs of patients with cancer and other serious diseases and improve their treatment outcomes. The company's goal in establishing its product line is to bring drugs to market in geographic areas where they believe they can maximize their value and have a meaningful impact on the therapeutic field.
